X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor

X4 Pharmaceuticals (XFOR) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome in the European Union. The positive opinion will now be reviewed by the European Commission with a final approval decision anticipated in the second quarter of 2026.